Related Experiment Videos
[Tumor markers: neoplasmas in digestive organs]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1996
Summary
Alpha-fetoprotein and des-gamma-carboxyprothrombin are key tumor markers for distinguishing hepatocellular carcinoma. Carbohydrate antigen 19-9 is a marker for pancreatic cancer, but tumor markers are best for post-treatment monitoring, not early diagnosis.
Area of Science:
- Oncology
- Biochemistry
Context:
- Hepatocellular carcinoma (HCC) diagnosis and monitoring.
- Pancreatic cancer diagnosis and monitoring.
- Clinical utility of tumor markers.
Purpose:
- To evaluate the clinical usefulness of alpha-fetoprotein (AFP), des-gamma-carboxyprothrombin (DCP), and carbohydrate antigen 19-9 (CA 19-9) as tumor markers.
- To assess their efficacy in differentiating liver and pancreatic cancers and for monitoring treatment response.
Summary:
- AFP and DCP are valuable, complementary markers for differentiating HCC from other liver diseases due to their high levels in HCC and lack of correlation.
- CA 19-9 is a typical marker for pancreatic cancer, but newer markers have not significantly improved its 65%-80% sensitivity.
- Tumor markers are not effective for early diagnosis of either cancer but are useful for post-treatment monitoring.
Impact:
- Provides insights into the diagnostic and monitoring capabilities of specific tumor markers in oncology.
- Highlights the limitations of current tumor markers for early cancer detection.
- Informs clinical practice regarding the appropriate use of AFP, DCP, and CA 19-9 in patient management.